Groowe Groowe / Newsroom / AMGN
⏱ News is delayed by 15 minutes. Sign in for real-time access. Sign in

AMGN News

Amgen Inc

Collibra Named Databricks' Governance Partner of the Year; Collibra and Databricks Deepening a Partnership to Ground Agentic AI in Governed Context

prnewswire.com
RIVN MA BABA UBER CMG ADI AMZN GOOG MSFT NVDA CRM PYPL IBM INTC ADBE NFLX HON GE BA CAT UNH PEP KO MCD COST WMT TMO ABBV XOM CVX JPM BAC WFC C GS MS DIS CMCSA VZ T SBUX NKE MDT AMGN GILD BMY PFE MRK JNJ PG LMT RTX GD LRCX MU AMD QCOM TXN AVGO AMAT KLAC ASML ENPH CRSP REGN VRTX BIIB AZN SNY LLY BNTX XCUR ALGN TDOC ZBRA ROKU UL

Latus Bio Appoints Bethany Mancilla as Chief Business Officer

businesswire.com
AMGN CRSP

AI-Driven Bispecific Antibody Development Attracts $1+ Billion in Pharma Investments Amid Clinical Risk Mitigation Focus

globenewswire.com
SNY PFE AMGN REGN

Marquis Who's Who Interviews and Honors Guy Plunkett III, PhD, for Excellence in Bacteriology, Genomics and Higher Education

accessnewswire.com
ALGN CRIS REGN GILD AMGN BIIB VRTX ILMN NTLA EDIT EXAS PACB NVDA AMD INTC MU GOOG MSFT IBM ORCL CRM ADBE CSCO ACN BABA JD PDD BIDU IQ HTHT XPEV NIO LI TSLA RIVN LCID F GM STLA VWAGY TM HMC AGNC PLTR SNOW DDOG SMCI ASML KLAC LRCX AMAT ADI TXN QCOM MCHP NXPI ON INFY WIT SAP HPQ DELL MSI AVGO MRVL WDC SE BILI EDU RLX BEKE TAL

Trust3 AI Joins NVIDIA Inception Program to Accelerate Adoption of Data and AI

prnewswire.com
NVDA SNOW AMGN AAPL CMCSA NTES INTU NWL ADSK Z

Harbour BioMed Secures Landmark Victory in U.S. Patent Infringement Case Against Amgen, Reshaping the Global Antibody Patent Landscape

prnewswire.com
AMGN

Global Heart Hub finds women delay seeking heart care by continuing to put others first

prnewswire.com
AMGN NVS

Patient Monitoring Devices Market worth $76.11 billion by 2031 | MarketsandMarkets™

prnewswire.com
MDT ABT DXCM GEHC BSX MASI BIIB AMGN GILD BMY MRK PFE JNJ BAX BOSC

Aspen Neuroscience Appoints Jeff Boerneke as General Counsel and Secretary

prnewswire.com
GOSS AMGN

GlycoNex Announces Positive Topline Results for Phase III Clinical Trial of Denosumab Biosimilar SPD8

prnewswire.com
AMGN